NMNAT2 is a druggable target to drive neuronal NAD production
James R. Tribble(Karolinska Institutet), Pete A. Williams(Karolinska Institutet), Baninia Habchi(Karolinska University Hospital), Raymond C.B. Wong(Centre for Eye Research Australia), Amin Otmani(Karolinska Institutet), Romanas Chaleckis(Nagoya City University), Evangelia Daskalakis(Karolinska University Hospital), Gauti Jóhannesson(University of Iceland), Jonathan Gilley(University of Cambridge), Andrea Loreto(The University of Sydney), Craig E. Wheelock(Karolinska University Hospital), Andrea Brancale(Cardiff University), Melissa Jöe(Karolinska Institutet), Alessio Canovai(University of Pisa), Michael P. Coleman(Babraham Institute), Carmine Varricchio(Cardiff University)
Cited by 36
Related Papers
Application of ’omics technologies to biomarker discovery in inflammatory lung diseases
|European Respiratory Journal|2013|270
Nicotinamide provides neuroprotection in glaucoma by protecting against mitochondrial and metabolic dysfunction
|Redox Biology|2021|227
Defining the Scope of Exposome Studies and Research Needs from a Multidisciplinary Perspective
|Environmental Science & Technology Letters|2021|153
Targeting NMNAT1 to Axons and Synapses Transforms Its Neuroprotective Potency<i>In Vivo</i>
|Journal of Neuroscience|2010|123
Fat-Secreted Ceramides Regulate Vascular Redox State and Influence Outcomes in Patients With Cardiovascular Disease
|Journal of the American College of Cardiology|2021|120